Metabolomic and lipidomic analyses reveal phosphatidylcholine–lysophosphatidylcholine axis alterations in sorafenib-persistent hepatocellular carcinoma - 07/11/26
Abstract |
Metabolic reprogramming and lipid remodeling are increasingly recognized as key processes underlying carcinogenesis and cancer treatment failure. The liver, as a central hub for lipid metabolism and homeostasis, is particularly susceptible to such alterations. Accordingly, hepatocellular carcinoma (HCC) exhibits extensive metabolic dysregulation and lipid remodeling, contributing to resistance to systemic therapies, including sorafenib. This study characterized histopathological and metabolic signatures across HCC carcinogenesis stages using a diethylnitrosamine/thioacetamide-induced rat model. Histopathological analysis confirmed gradual progression from inflammation to cirrhosis and finally HCC, based on non-alcoholic fatty liver disease activity scoring and non-alcoholic steatohepatitis fibrosis staging. Metabolomic profiling revealed stage-specific metabolic patterns throughout disease progression, with a marked shift toward lipid-centric metabolism during fibrosis and in sorafenib-persistent tumors, defined here as cancer cells that survive sorafenib treatment. These metabolic changes highlight the role of lipid remodeling in both early carcinogenesis and systemic treatment tolerance. Furthermore, lipidomic analysis of sorafenib-persistent HCC demonstrated significant accumulation of lysophosphatidylcholine (LPC)(20:4) and depletion of precursor phosphatidylcholine species, demonstrating alterations to the phosphatidylcholine-lysophosphatidylcholine axis. Given that cytosolic phospholipase A2 (cPLA2) is a key enzyme that hydrolyzes phosphatidylcholine to generate lysophosphatidylcholine, we hypothesized that cPLA2 may contribute to the observed lipid imbalance. Mechanistic validation in sorafenib-treated HepG2 cells using the cPLA2 inhibitor AACOCF3 showed increased sorafenib sensitivity, enhanced apoptosis, and reduced clonogenicity upon cPLA2 inhibition. Collectively, these findings identify phosphatidylcholine-lysophosphatidylcholine axis alteration as a potential driver of cancer cell survival under sorafenib treatment and highlight lipid metabolic reprogramming as a sorafenib-re-sensitization target in HCC.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
A DEN/TA-induced rat model was used to recapitulate sequential stages of hepatocarcinogenesis—healthy, inflammation, fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and sorafenib-persistent HCC—and metabolic profiling across these stages revealed distinct, stage-specific metabolic signatures. Progression from HCC to sorafenib-persistent HCC was accompanied by alterations in phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) levels, pointing to a shift along the PC-to-LPC axis as a feature of sorafenib persistence, with cPLA2 implicated as a candidate mediator of this conversion. Pharmacological inhibition of cPLA2 with AACOCF3 in HepG2 and HuH-7 cells increased sorafenib sensitivity and partially restored the PC–LPC balance, suggesting that this metabolic reprogramming could represent a targetable avenue for treatment development in HCC.
A DEN/TA-induced rat model was used to recapitulate sequential stages of hepatocarcinogenesis—healthy, inflammation, fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and sorafenib-persistent HCC—and metabolic profiling across these stages revealed distinct, stage-specific metabolic signatures. Progression from HCC to sorafenib-persistent HCC was accompanied by alterations in phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) levels, pointing to a shift along the PC-to-LPC axis as a feature of sorafenib persistence, with cPLA2 implicated as a candidate mediator of this conversion. Pharmacological inhibition of cPLA2 with AACOCF3 in HepG2 and HuH-7 cells increased sorafenib sensitivity and partially restored the PC–LPC balance, suggesting that this metabolic reprogramming could represent a targetable avenue for treatment development in HCC. Le texte complet de cet article est disponible en PDF.
Highlights |
• | Metabolomics reveals stage-specific signatures across HCC progression. |
• | Fibrosis marks a critical metabolic transition toward lipid remodeling. |
• | Sorafenib-persistent HCC shows PC-to-LPC axis alteration. |
• | cPLA2 hydrolyzes PC to LPC; its inhibition increased sorafenib sensitivity. |
Keywords : Hepatocellular carcinoma, Metabolomics, Lipidomics, Phosphatidylcholine-lysophosphatidylcholine-axis, Cytosolic phospholipase A2 (cPLA2), Sorafenib-persistence
Plan
Vol 204
Article 119977- novembre 2026 Retour au numéro
Article précédent
- Sunitinib induces senolysis associated with modulation of platelet-derived growth factor receptor beta
- Hyun-Ji Cho, Sung Jin Ryu, Byung Ju Kim, Jeong-A Hwang, Ahyeon Yun, Eok-Cheon Kim, Jae-Ryong Kim, Tae Jun Park, Sung Bae Lee, Young Zoon Kim, Yun-Il Lee, Sang Chul Park, Young-Sam Lee
- Integrated experimental and network pharmacology evaluation of a defined phytochemical combination in diabetes-related models
- Vadlapudi Kumar, H.L. Raghavendra, Poorna Vivek Valleti, D.V. Poornima, T. Manjunatha
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?